Show an ad over header. AMP

I am the FIRST

Alzheimer's drug decision to test FDA's rigor

The FDA will soon decide the fate of Biogen's experimental Alzheimer's drug. But there is one glaring issue — there is no conclusive evidence the drug effectively treats the crippling neurological disease.

Why it matters: This will be one of the FDA's most important decisions in years. The outcome will show whether the federal agency sides with the overwhelming scientific consensus that the drug isn't proven to work, or with an industry and a patient population desperate for anything to be approved.


The background: Two years ago, Biogen halted two clinical trials of its infused drug, aducanumab.

  • But the company looked again at the clinical trial data and argued one of the failed trials suggested some benefit for Alzheimer's patients on a higher dose of the drug. The other trial still failed.
  • The FDA generally wants "two adequate and well-controlled trials" for drug approval, although it does on rare occasions consider one well-controlled trial with "confirmatory evidence."
  • Biogen applied for FDA approval last summer.

Where things stand: Independent physicians, statisticians, drug researchers and others in the field have urged the FDA to reject the drug, warning the study supporting aducanumab is small, flawed and possibly a false positive. Side effects like brain swelling have also raised concerns.

  • The most notable dissent came during the FDA's advisory committee meeting last November, when none of the 11 members voted in favor of the drug's approval.
  • "What's the point of an advisory committee if you approve this? The FDA just doesn't consider your opinion at all," said Brian Skorney, a pharmaceutical stock analyst at Baird who added it would be a "huge misstep for the agency" to approve the drug.
  • The FDA's statistical reviewer of aducanumab said there was "no compelling substantial evidence of treatment effect or disease slowing and that another study is needed."
  • David Knopman, a Mayo Clinic neurologist who oversaw the aducanumab trials, previously said the drug's evidence was "terribly weak." He told Axios he believes Biogen needs to run another clinical trial, and the company could have been close to finishing if it had done so two years ago.

The other side: Biogen did not make executives available for an interview and would not answer questions on the record. The company's market value will plummet if aducanumab doesn't get approval.

  • Many physicians and scientists who support aducanumab's approval have financial ties to Biogen and Eisai, which also developed the drug.
  • Alzheimer's patients who tried the drug, and their families, are looking for any kind of treatment that stops the disease's progression and broadly want the FDA to approve the drug despite the dearth of evidence.
  • "There's a dire and drastic need to offer relief," said Joanne Pike, a top executive at the Alzheimer's Association. She said the organization "respectfully disagrees" with the FDA's expert committee. When asked if Biogen should have started another trial two years ago or if Biogen should start another trial if the drug isn't approved, she said, "I'm not going to comment on that."

The bottom line: "The FDA's credibility would take an enormous hit if this product is approved," Caleb Alexander, a physician and drug researcher at Johns Hopkins who was on the FDA's advisory committee for this drug, told Axios. "It's important they get it right. There's no reason they should follow the science any less here."

Why the startup world needs to ditch "unicorns" for "dragons"

When Aileen Lee originally coined the term "unicorn" in late 2013, she was describing the 39 "U.S.-based software companies started since 2003 and valued at over $1 billion by public or private market investors."

Flashback: It got redefined in early 2015 by yours truly and Erin Griffith, in a cover story for Fortune, as any privately-held startup valued at $1 billion or more. At the time, we counted 80 of them.

Keep reading... Show less

Scoop: Facebook's new moves to lower News Feed's political volume

Facebook plans to announce that it will de-emphasize political posts and current events content in the News Feed based on negative user feedback, Axios has learned. It also plans to expand tests to limit the amount of political content that people see in their News Feeds to more countries outside of the U.S.

Why it matters: The changes could reduce traffic to some news publishers, particularly companies that post a lot of political content.

Keep reading... Show less

Scoop: Amazon quietly getting into live audio business

Amazon is investing heavily in a new live audio feature that's similar to other live audio offerings like Clubhouse, Twitter Spaces and Spotify's new live audio platform, sources tell Axios.

Why it matters: As with Amazon's efforts in podcasting and music subscriptions, the company sees live audio as a way to bolster the types of content it can offer through its voice assistant, Alexa, and its smart speaker products.

Keep reading... Show less

Hurricane Ida exposes America's precarious energy infrastructure

The powerful hurricane that plunged New Orleans into darkness for what could be weeks is the latest sign that U.S. power systems are not ready for a warmer, more volatile world.

The big picture: “Our current infrastructure is not adequate when it comes to these kinds of weather extremes,” Joshua Rhodes, a University of Texas energy expert, tells Axios.

Keep reading... Show less

"We must go further": 70% of adults in European Union are fully vaccinated

About 70% of adults in the European Union are fully vaccinated against COVID-19, Ursula von der Leyen, the president of the European Commission, said Tuesday.

Why it matters: The milestone makes the E.U. one of the world's leaders in inoculations, after an initially lagging vaccine campaign, the New York Times notes.

Keep reading... Show less

What Elizabeth Holmes jurors will be asked ahead of fraud trial

Jury selection begins today in USA v. Elizabeth Holmes, with the actual jury trial to get underway on Sept. 8.

Why it matters: Theranos was the biggest fraud in Silicon Valley history, putting both hundreds of millions of dollars and thousands of patients' health at risk.

Keep reading... Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories